The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 19 of the 79 sources its claims cite were checked for support.
Abstract
The fine line between human health and disease can be driven by the interplay between host and microbial factors. This “metagenome” regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 43 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“16S ribosomal RNA (rRNA)-based sequencing of gene amplicons and shotgun DNA sequencing of patient stool samples have identified subsets of bacteria more abundant in responding versus nonresponding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
The patient-stool analysis and Fig. 4 caption (page unavailable in our copy) identify bacterial clusters with differing Bacteroides abundance, and the paper reports 16S rRNA gene-amplicon sequencing of feces. But the treatment-response comparison was between mice receiving stool from different patient clusters, not responding versus nonresponding patients; our copy also does not report shotgun DNA sequencing of patient stool. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The indexed passage labeled Abstract (page not supplied) reports 16S rRNA sequencing of mouse fecal samples and identifies Bifidobacterium as associated with stronger antitumor responses. It does not report shotgun DNA sequencing or a comparison of responding and nonresponding patients; a later passage proposes sequencing patient stool as future work. (LLM, conf=0.88)
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The supplied passages (labelled Abstract; page not provided) describe 16S rRNA gene amplicon sequencing and metagenomic shotgun sequencing of patient stool samples. They report bacterial species differentially enriched in responders and nonresponders, including eight more abundant in responders. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accordingly, B. fragilis and Burkholderia cepacia administered via gavage to mice reduced the severity of colitis induced by mAb to CTLA-4 (13,22).”
What the sources say
- Supportedcites [13] source
The passage labeled Abstract (discussion of Fig. 3A; page not provided) reports that reconstituting antibiotic-treated mice with a combination of B. fragilis and B. cepacia reduced histopathological signs of colitis induced by CTLA-4 blockade. The Fig. 3 caption describes oral gavage and assessment of colonic lesions in those mice. (LLM, conf=0.94)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
The Results section, “Members of Bacteroidetes phylum associated with resistance” (page unavailable), reports an association between Bacteroidetes abundance and resistance to colitis in melanoma patients. Our copy does not address whether gavage with B. fragilis and Burkholderia cepacia reduced colitis severity in mice; searches for both species and for mouse gavage found no such passage. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In patients with metastatic melanoma treated with the checkpoint inhibitor ipilimumab (antibody to CTLA-4), the abundance of Bacteroidetes inversely correlated with the severity of colitis (22).”
What the sources say
- Supportedcites [22] source
The Results section (‘Members of Bacteroidetes phylum associated with resistance’; page not provided) says the authors stratified patients by inflammation severity and found Bacteroidetes more abundant in colitis-free patients. The Methods identify the patients as adults with metastatic melanoma who received ipilimumab. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a study performed in 541 patients with hematologic malignancies reported that the gut microbiome at diagnosis influenced the probability of relapse within 2 years after ASCT.”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Methods and Results (page not provided) describe 541 patients with hematologic malignancies and assess microbiota associations with relapse or disease progression over two years. But the study concerns allogeneic HCT, not ASCT; its main cohort had stool samples collected within three weeks after transplantation, not at diagnosis. The Discussion describes an association, not evidence that the microbiome caused or influenced relapse. (LLM, conf=0.90)
plainstates an associationn = 541- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Given these considerations, it is perhaps even more striking that bacteria generally associated with health (such as Clostridiales, Ruminococcacae, Faecalibacterium spp., Akkermansia muciniphila, B. fragilis,a n dBifidobacteria) (13, 14, 18-20) or immunogenicity (Enterococci, Collinsella, and Alistipes)( 11, 13, 14, 20) were found to be abundant in responding patients.”
What the sources say
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
In the paper’s discussion of Fig. 4, stools from one patient microbiome cluster promoted colonization by immunogenic B. fragilis and B. thetaiotaomicron, and mice receiving those stools responded to CTLA-4 blockade. The passage does not establish that these bacteria were more abundant in patients who responded to treatment; the reported treatment responses were in recipient mice. It also does not support the sentence’s full list of bacteria. (LLM, conf=0.87)
- Not checked yetcites [14] source
- Not checked yetcites [18] source
- Not checked yetcites [19]
- Supportedcites [20] source
The passage labeled Abstract reports that Enterococcus faecium and Collinsella aerofaciens were among eight species more abundant in responding patients. These support the immunogenic-bacteria portion of the cited sentence; the paper does not need to establish every organism listed alongside other citations. (LLM, conf=0.92)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The paper’s indexed text (labeled Abstract; page unavailable) reports that Alistipes correlated positively with TNF production and that giving A. shahii to mice restored a tumor-associated immune response. This supports an immunogenic role for Alistipes, but the study does not show that it—or the other named bacteria—was abundant in responding patients. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
33 more claims · 2 with their cited sources checked
Create a free account to see all 67 claims and to verify the 60 references still open.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Particularly, immune checkpoint inhibitory (ICI) therapy and adoptive cell therapy using tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) can be influenced by the composition of the intestinal microbiota4,5.”
From Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their gene count that exceeds the human genome’s gene count by ~100-fold and enables diverse metabolic programming”
From The microbiome and human cancer (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, following the epidemiological demonstration of the negative effect of antibiotics on the efficacy of ICIs13,42,90, specific microbial taxa have been associated with response or resistance to ICIs across distinct cancer types26,38–40,42,91–100.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“their effects on host immune system development and activity, including antitumor immunosurveillance (27–31).”
From The microbiome and human cancer (2021) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The gut microbiome and immuno-oncology
“immunotherapy through a combination of TLR9 antagonist and antibody to interleukin-10R (IL-10R) (11)”
§ The gut microbiome and immuno-oncology
“The immunizing effects of antibody to IL-10R + the TLR9 agonist CpG”
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
Self-citationRetractedGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Self-citationDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cited by
Items 301–400 of 793
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 32
Immunostimulatory gut bacteria
Zitvogel, L., & Kroemer, G. (2019) · Science · doi:10.1126/science.aaz7595 · Cited by 27
Self-citationPAK4 as a cancer immune-evasion target
Gajewski, T. F., & Fessler, J. L. (2020) · Nature Cancer · doi:10.1038/s43018-019-0012-z · Cited by 26
Self-citationGut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
Eiman, L., Moazzam, K., Anjum, S., Kausar, H., Sharif, E. A. M., & Ibrahim, W. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575452 · Cited by 32
Tegegne, B. A., Abebaw, D., Teffera, Z. H., Fenta, A., Belew, H., Belayneh, M., Jemal, M., Getinet, M., Baylie, T., Tamene, F. B., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502118r · Cited by 26
Dietary intervention as a therapeutic for cancer
Morita, M., Kudo, K., Shima, H., & Tanuma, N. (2020) · Cancer Science · doi:10.1111/cas.14777 · Cited by 28
Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment
Zhao, X., Liu, Z., & Chen, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030948 · Cited by 28
“The possible immunoregulatory effects of microbes are hypothetically achieved through its stimulatory effect of microbial antigens on the T cell response, the engagement of pattern recognition receptors and the release of microbial metabolites [84].”
BackgroundPembrolizumab for the treatment of gastric cancer
Kamath, S. D., Kalyan, A., & Benson, A. B. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1526084 · Cited by 26
“tumor antigens or cause tumor-specific antigen recognition [51].”
BackgroundLee, J., Lee, E., Hong, S., Kim, D., Eunju, O., Sprent, J., Im, S., Lee, Y. J., & Surh, C. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1681869 · Cited by 25
“However, their response rate is about 20–30%, and there is a critical need to combine other therapeutic modalities such as conventional chemo-radiotherapy, intestinal microbiome or immunological adjuvants to enhance its efficacy.(34,35) Of them, IL-2 is one of the best candidates to expand immune cells in the body, an…”
BackgroundAssociation of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis
Peppas, I., George, G., Sollie, S., Josephs, D. H., Hammar, N., Walldius, G., Karagiannis, S. N., & Hemelrijck, M. V. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0953 · Cited by 28
Innao, V., Allegra, A. G., Musolino, C., & Allegra, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238902 · Cited by 37
PD ‐1/ PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity
Hosseinzadeh, R., Feizisani, F., Shomali, N., Abdelbasset, W. K., Hemmatzadeh, M., Navashenaq, J. G., Jadidi‐Niaragh, F., Bokov, D. O., Janebifam, M., & Mohammadi, H. (2021) · IUBMB Life · doi:10.1002/iub.2558 · Cited by 26
“In contrast, FMT of feces from nonresponder patients (who did not show clinical response to immune checkpoint blockade) would reveal the nonfavorable microbiota composition.(62) FMT studies identified several bacteria (as mentioned above), which improved the efficacy of ICBT.”
ResultIleal immune tonus is a prognosis marker of proximal colon cancer in mice and patients
Picard, M., Yonekura, S., Slowicka, K., Petta, I., Rauber, C., Routy, B., Richard, C., Iebba, V., Tidjani Alou, M., Becharef, S., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00684-w · Cited by 24
Self-citationIntestinal microbiota regulates anti‐tumor effect of disulfiram combined with Cu2+ in a mice model
Hu, H., Cui, L., Lu, J., Wei, K., Wei, J., Li, S., Zou, C., & Chen, T. (2020) · Cancer Medicine · doi:10.1002/cam4.3346 · Cited by 24
Lower Airway Dysbiosis Exacerbates Lung Cancer
Zitvogel, L., & Kroemer, G. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1641 · Cited by 26
Self-citationTomasi, M., Caproni, E., Benedet, M., Zanella, I., Giorgetta, S., Dalsass, M., König, E., Gagliardi, A., Fantappiè, L., Berti, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.912639 · Cited by 25
Challenges in maintaining the probiotic potential in alcoholic beverage development
dos Santos, D. C., Filho, J. G. D. O., Andretta, J. R., Silva, F. G., & Egea, M. B. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.102485 · Cited by 27
Wang, S., Xu, B., Zhang, Y., Chen, G., Zhao, P., Gao, Q., & Yuan, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0376 · Cited by 32
“…possible mechanisms underlying the interaction between intestinal flora and the host immune system: (1) through microbial antigen-induced T cell responses; (2) through pattern recognition receptors involved in the immune response; and (3) through metabolism to produce immunoreactive substances 6 .”
BackgroundWang, W., Fan, J., Zhang, C., Huang, Y., Chen, Y., Fu, S., & Wu, J. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127668 · Cited by 25
Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future
Parisi, A., Porzio, G., & Ficorella, C. (2020) · Cancers · doi:10.3390/cancers12092598 · Cited by 25
“Gut microbiome has been shown to be associated with efficacy of anti-PD1 mAb in different types of cancer [76] and the DELIVER trial (JACCRO GC-08, UMIN000030850) is investigating the role of novel immune-related biomarkers (gut microbiome, genetic polymorphism, gene expression, and metabolome in plasma) in mGC patien…”
BackgroundBacteriocin production by mucosal bacteria in current and previous colorectal neoplasia
Kohoutová, D., Forstlova, M., Morávková, P., Cyrany, J., Bosák, J., Šmajs, D., Rejchrt, S., & Bureš, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-6512-5 · Cited by 24
The effect of probiotics supplementation in postoperative cancer patients: a prospective pilot study
Kwon, H., Chae, S. H., Jung, H. J., Shin, H., Ban, O., Yang, J., Kim, J. H., Jeong, J. E., Jeon, H. M., Kang, Y. W., et al. (2021) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2021.101.5.281 · Cited by 23
“In fact, the principal aim of administrating probiotics to cancer patients is to repopulate Lactobacillus in the gut microbiota of compromised patients, thus reestablishing the levels and functionality of the commensal bacteria depleted after treatment [26].”
BackgroundImmunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer
AL-Ishaq, R. K., Koklesová, L., Kubatka, P., & Büsselberg, D. (2022) · Cancers · doi:10.3390/cancers14092140 · Cited by 24
Fecal Microbiota Restoration Modulates the Microbiome in Inflammation-Driven Colorectal Cancer
Gates, T. J., Yuan, C., Shetty, M., Kaiser, T., Nelson, A., Chauhan, A., Starr, T. K., Staley, C. M., & Subramanian, S. (2023) · Cancers · doi:10.3390/cancers15082260 · Cited by 24
“It is being explored in many colon diseases, including recurrent Clostridiodes difficile infection24, irritable bowel disease,25,26 and CRC.27 Further, it has been shown that cohousing of animals can modulate the microbiome between mice through horizontal microbiome transfer (HMT).28 The longitudinal effects on the gu…”
BackgroundInfluentialLi, M., Wu, B., Li, L., Lv, C., & Tian, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188945 · Cited by 25
Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
Re, V. D., Caggiari, L., Repetto, O., Mussolin, L., & Mascarin, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101596 · Cited by 25
Role of gut microbiome on immunotherapy efficacy in melanoma
Bibbò, S., Ianiro, G., Giambò, F., Settanni, C. R., Cammarota, G., & Gasbarrini, A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1926759 · Cited by 25
“Intestinal microbiota substantially influences the efficacy of cancer immunotherapy.(21) Thus, the modulation of gut microbiota was proposed as new tool to improve cancer immunotherapy efficacy and was suggested to decrease related adverse effects.”
BackgroundAccomplishment of probiotics in human health pertaining to immunoregulation and disease control
Varsha, K. K., Arun Padmakumar, M., & Nampoothiri, K. M. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.06.020 · Cited by 28
Xu, H., Leng, J., Liu, F., Chen, T., Qu, J., Yang, Y., Ning, C., Ke, X., Xiao, B., Zhang, Y., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38310 · Cited by 24
“The intratumoral microbiota, including bacteria [8,9], fungi [10], and viruses [11], plays an influential role in cancer initiation, tumor progression, and responses toward cancer therapies [12].”
BackgroundChoi, S.-W., Kim, J. H., Hong, J., & Kwon, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568590 · Cited by 25
A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine
Mokhtari, R. B., Sambi, M., Shekari, F., Satari, K., Ghafoury, R., Ashayeri, N., Eversole, P., Baluch, N., Harless, W. W., Muscarella, L. A., et al. (2025) · Biomolecules · doi:10.3390/biom15091304 · Cited by 25
Rational combination of cancer immunotherapy in melanoma
Mandalà, M., & Rutkowski, P. L. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2506-y · Cited by 23
Metagenomics Analysis of Breast Microbiome Highlights the Abundance of Rothia Genus in Tumor Tissues
Kartti, S., Bendani, H., Boumajdi, N., Bouricha, E. M., Zarrik, O., Agouri, H. E., Fokar, M., Aghlallou, Y., Jaoudi, R. E., Belyamani, L., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030450 · Cited by 22
“This can be used to identify a link between this microbiome and response to treatment [13,14].”
BackgroundSingh, V. P., Shirbhate, E., Kore, R., Vishwakarma, S., Parveen, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575320344240625080555 · Cited by 23
Pradeu, T. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108616706 · Cited by 149
“environment includes the tissue context located at the vicinity of the tumor (sometimes called the tumor microenvironment), but also elements located quite remotely from the tumor in the organism (such as some immuneassociated organs and the microbiota, which recently has been proven to influence cancer progression an…”
BackgroundAn ambient temperature collection and stabilization strategy for canine microbiota studies
Lin, C.-Y., Cross, T.-W., Doukhanine, E., & Swanson, K. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-70232-6 · Cited by 24
Effect of Streptococcus anginosus on biological response of tongue squamous cell carcinoma cells
Xu, Y., Jia, Y., Chen, L., Gao, J., & Yang, D. (2021) · BMC Oral Health · doi:10.1186/s12903-021-01505-3 · Cited by 21
Lin, J., Zhang, J., Zhou, R., Guo, L., Liu, D., Rong, M., Kong, M. G., & Ostrikov, K. (2022) · Water Research · doi:10.1016/j.watres.2022.119174 · Cited by 21
Sui, L., Wang, L., Han, M., Fan, H., Tang, H., Gao, H., Li, G., Xu, Z., Zhou, Z., Du, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1532528 · Cited by 23
“These responses either support tumor-speci fi c immune activation or may cross-react with tumor-speci fi c antigens (12, 13).”
Microbial biomarkers for immune checkpoint blockade therapy against cancer
Adachi, K., & Tamada, K. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1492-9 · Cited by 23
Gündüz, M., Murakami, D., Gündüz, İ., Tamagawa, S., Hiraoka, M., Sugita, G., & Hotomi, M. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.08.020 · Cited by 22
Leng, J., Xu, H., Liu, X., Yang, Y., Ning, C., Sun, L., Qu, J., Ke, X., & Lan, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01320-6 · Cited by 20
The Implication of Gastric Microbiome in the Treatment of Gastric Cancer
Pappas‐Gogos, G., Tepelenis, K., Fousekis, F., Katsanos, K. H., Pitiakoudis, M. S., & Vlachos, K. (2022) · Cancers · doi:10.3390/cancers14082039 · Cited by 23
Wei, Q., Zhang, Q., Wu, Y., Han, S., Yin, L., Zhang, J., Gao, Y., Shen, H., Jing, Z., Chu, J., et al. (2023) · Discover Oncology · doi:10.1007/s12672-023-00612-7 · Cited by 21
Russo, G. L., Prelaj, A., Dolezal, J. M., Beninato, T., Agnelli, L., Triulzi, T., Fabbri, A., Lorenzini, D., Ferrara, R., Brambilla, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006833 · Cited by 22
Diversification and deleterious role of microbiome in gastric cancer
Chattopadhyay, I., Gundamaraju, R., & Rajeev, A. (2023) · Cancer Reports · doi:10.1002/cnr2.1878 · Cited by 23
The role of extratumoral and intratumoral microorganisms in cancer immunotherapy
Du, Y., Liu, L., Ma, W., Yan, W., Mao, W., Du, Y., Cui, K., Pu, Y., Li, Z., Sansonetti, P. J., et al. (2023) · The Innovation Life · doi:10.59717/j.xinn-life.2023.100016 · Cited by 21
It Is All about Probiotics to Control Cervical Cancer
Ashique, S., Faruk, A., Ahmad, F. J., Khan, T., & Mishra, N. (2023) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-023-10183-2 · Cited by 22
“Probiotics and anti-cancer drugs are administered orally to promote a healthy intestinal microbiome and reduce the severe gastrointestinal side effects frequently associated with anti-cancer treatments [25–27].”
Deng, X., Zhang, C., Yang, Y., Wang, J., Ye, X., Gu, J., Zhang, X., & Jin, H. (2023) · Journal of Cancer · doi:10.7150/jca.88854 · Cited by 21
“Studies have found that the use of antibiotics can cause intestinal flora dysbiosis, significantly reducing the effect of PD-1 antibody [11].”
BackgroundČierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 24
“Preclinical murine models and clinical cohorts show that the gut microbiota significantly influences the efficacy and side effects of ICIs, and intestinal dysbiosis can lead to treatment resistance [37–40].”
Role and potential clinical utility of ARID1A in gastrointestinal malignancy
Wang, R., Chen, M., Ye, X., & Poon, K. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108360 · Cited by 24
Pak, S., Kim, S., Kim, S. H., Joung, J. Y., Park, W. S., Chung, J., Lee, K. H., & Seo, H. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.570077 · Cited by 22
Zhang, J., Dai, Z., Yan, C., Zhang, W., Wang, D., & Tang, D. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02659-w · Cited by 21
Tudorache, M., Treteanu, A. R., Pîrcălăbioru, G. G., Lixandru-Petre, I.-O., Bolocan, A., & Andronic, O. (2025) · Cancers · doi:10.3390/cancers17142294 · Cited by 20
“The human microbiome—especially the gut microbiota—has become recognized as a key regulator of host immune responses and a major factor influencing the success of cancer immunotherapy [57].”
Kaźmierczak-Siedlecka, K., Ruszkowski, J., Skonieczna‐Żydecka, K., Jędrzejczak, J., Folwarski, M., & Makarewicz, W. (2021) · Central European Journal of Immunology · doi:10.5114/ceji.2020.103353 · Cited by 22
The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer
Guo, Q., Qin, H., Liu, X., Zhang, X., Chen, Z., Qin, T., Chang, L., & Zhang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915047 · Cited by 25
Morgan, M. P., Finnegan, E., & Das, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.002 · Cited by 20
Methionine-producing tumor micro(be) environment fuels growth of solid tumors
Vega, A. A., Marshall, E. A., Noonan, A. J. C., Filho, F. S. L., Yang, J., Stewart, G. L., Johnson, F. D., Vucic, E. A., Pewarchuk, M. E., Shah, P. P., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00832-7 · Cited by 21
“Dysbio-sis, or changes in the microbiome structure, have also been observed in several studies of lung cancer biopsies, while the presence of specific bacterial species in the gut has been associated with response to checkpoint blockade in lung cancer patients [26].”
The effect mechanism of polysaccharides inhibit tumor immune escape: A review
Yang, K., Chen, J., Chen, J., Wang, Z., Song, B., Li, R. Q., Zhong, S., & Cheong, K. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105638 · Cited by 22
Integrating tumor genomics into studies of the microbiome in colorectal cancer
Burns, M. B., & Blekhman, R. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1549421 · Cited by 24
“In our recent study we aimed to assess the effect of host genetics on the microbiome in the context of CRC.”
BackgroundInfluentialThe Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?
Brandi, G., Turroni, S., McAllister, F. M., & Frega, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189914 · Cited by 21
Heymann, C. J. F., Bobin‐Dubigeon, C., Muñoz-García, J., Cochonneau, D., Ollivier, E., Heymann, M., & Heymann, D. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100451 · Cited by 22
“This tumour ecosystem has a strong influence on cancer cell proliferation/apoptosis/migration, tissue vascularisation, immune response and also contributes to the control of drug sensitivity or resistance [2,3].”
BackgroundSpiliopoulou, P., Vornicova, O., Genta, S., & Spreafico, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021294 · Cited by 20
Acquired Resistance to Immune Checkpoint Blockade Therapies
Zhao, X., Wangmo, D., Robertson, M. J., & Subramanian, S. (2020) · Cancers · doi:10.3390/cancers12051161 · Cited by 21
Cheng, X., Wang, J., Gong, L., Dong, Y., Shou, J., Pan, H., Yu, Z., & Fang, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185479 · Cited by 20
“For example, an increase in the permeability of the upper gastrointestinal tract could lead to the translocation of Enterococcus hirae from the small intestine to the spleen, as well as the accumulation of Barnesiella intestinihominis in the colon, which causes a coordinated immune-stimulatory effect on antitumor immu…”
BackgroundMicrobiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
Mishra, S., Amatya, S. B., Salmi, S., Koivukangas, V., Karihtala, P., & Reunanen, J. (2022) · Cancers · doi:10.3390/cancers14205121 · Cited by 19
“Possible mechanisms have been hypothesized as [38]:”
BackgroundInfluentialResearch progress on prognostic factors of gallbladder carcinoma
Miao, W., Liu, F., Guo, Y., Zhang, R., Wang, Y., & Xu, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05975-0 · Cited by 20
“The gut microbiota is increasingly recognized as an important factor related to tumor development and anticancer treatment effects (Kitamoto et al. 2020; Zitvogel et al. 2018).”
BackgroundThe roles of homologous recombination and the immune system in the genomic evolution of cancer
Nandi, B., Talluri, S., Kumar, S., Yenumula, C., Gold, J. S., PRABHALA, R. H., Munshi, N. C., & Shammas, M. A. (2018) · Journal of Translational Science · doi:10.15761/jts.1000282 · Cited by 19
“The efficacy of checkpoint inhibitors has also been shown to depend on the composition of the microbiota [65].”
BackgroundLiu, L., Wu, J., Gao, J., & Lu, X. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000893 · Cited by 18
Impact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
Self-citationCommensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines
Tomasi, M., Dalsass, M., Beghini, F., Zanella, I., Caproni, E., Fantappiè, L., Gagliardi, A., Irene, C., König, E., Frattini, L. F., et al. (2021) · Vaccines · doi:10.3390/vaccines9111356 · Cited by 21
“A number of not mutually exclusive mechanisms have been postulated [3,4].”
BackgroundBeattie, J., Yarmus, L. B., Wahidi, M. M., Rivera, M. P., Gilbert, C. R., Maldonado, F., Czarnecka, K., Argento, A. C., Chen, A. J., Herth, F. J. F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2539pp · Cited by 19
Ferravante, C., Memoli, D., Palumbo, D., Ciaramella, P., Loria, A. D., D’Agostino, Y., Nassa, G., Rizzo, F. M., Tarallo, R., Weisz, A., et al. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04004-y · Cited by 18
Animal Models in Toxicologic Research: Rodents
Clements, P., Bolon, B. N., McInnes, E. F., Mukaratirwa, S., & Scudamore, C. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00011-x · Cited by 17
Mattiola, I., & Diefenbach, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101724 · Cited by 19
Akkermansia muciniphila improves gastric cancer treatment by modulating the immune microenvironment
Fang, J., Zhang, H., Zhang, X., Lu, X., Liu, J., Li, H., & Huang, J. (2024) · Future Microbiology · doi:10.2217/fmb-2023-0210 · Cited by 18
Wongsurawat, T., Nakagawa, M., Atiq, O. T., Coleman, H. N., Jenjaroenpun, P., Allred, J. I., Trammel, A. B., Puengrang, P., Ussery, D. W., & Nookaew, I. (2019) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2019.105739 · Cited by 17
The role of non-apoptotic cell death in the treatment and drug-resistance of digestive tumors
Yang, Y., Bai, L., Liao, W., Feng, M., Zhang, M., Wu, Q., Zhou, K., Wen, F., Lei, W., Zhang, N., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112678 · Cited by 19
Bourbonne, V., Geier, M., Schick, U., & Lucia, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061237 · Cited by 17
Use of the microbiome in the management of children with type 2 diabetes mellitus
Brar, P. C., & Kohn, B. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000781 · Cited by 17
The microbiota in radiotherapy-induced cancer immunosurveillance
Chen, J., Deutsch, É., Kroemer, G., Galluzzi, L., & Zitvogel, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01052-8 · Cited by 19
“Strongly supporting the notion that chronic inflammation-associated dysbiosis paves the way to resistance to immunotherapy, distinct gut microbiota signatures have been shown to correlate with the outcomes of patients with cancer receiving ICIs 63 .”
Self-citationSater, A. H. A., Bouferraa, Y., Amhaz, G., Haibe, Y., Lakkiss, A. E., & Shamseddine, A. I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.804983 · Cited by 17
“A spectrum of diseases including cancer and immune disorders have been associated with gut microbiome disruption (94, 95).”
BackgroundPromising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou, P., Lopes, C. D. H., & Spreafico, A. (2023) · Cells · doi:10.3390/cells13010019 · Cited by 16
Xu, J., Tian, Y., Zhao, B., Hu, D., Wu, S., Ma, J., & Yang, L. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00200-3 · Cited by 16
“Recent studies have shown that the gut microbiota can regulate antitumor immunity [36–38].”
Dóra, D., Kiraly, P., Somodi, C., Ligeti, B., Dulka, E., Gálffy, G., & Lohinai, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05835-y · Cited by 18
“The intestinal microbiome’s role as an anti-tumor response mediator has been under intense scrutiny lately, with a special focus on ICI and chemotherapy (CHT) treatments [4–7].”
Daillère, R., Routy, B., Goubet, A., Cogdill, A. P., Ferrere, G., Silva, C. A.-C., Fluckiger, A., Ly, P., Haddad, Y., Pizzato, E., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1794423 · Cited by 17
Self-citationMusic of metagenomics—a review of its applications, analysis pipeline, and associated tools
Wajid, B., Anwar, F., Wajid, I., Nisar, H., Meraj, S., Zafar, A., AlShawaqfeh, M. K., Ekti, A. R., Khatoon, A., & Suchodolski, J. S. (2021) · Functional & Integrative Genomics · doi:10.1007/s10142-021-00810-y · Cited by 17
Chemoproteomic Analysis of Microbiota Metabolite–Protein Targets and Mechanisms
Zhao, X., Yang, X., & Hang, H. C. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00758 · Cited by 16
Feunteun, J., Ostyn, P., & Delaloge, S. (2022) · iScience · doi:10.1016/j.isci.2022.104217 · Cited by 20
“Microbiota is also considered as an influent regulator of cancer, at every stage of its development (Dzutsev et al., 2017) and its impact on the clinical efficacy of therapies against extra-intestinal tumors is well documented (Zhouet al., 2021; Zitvogel et al., 2018).”
BackgroundPomej, K., Balcar, L., Scheiner, B., Semmler, G., Meischl, T., Mandorfer, M., Reiberger, T., Müller, C., Trauner, M., & Pinter, M. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s317957 · Cited by 17
Cancer immunity thwarted by the microbiome
Hartmann, N., & Kronenberg, M. (2018) · Science · doi:10.1126/science.aat8289 · Cited by 17
Defining the immunogram of breast cancer: a focus on clinical trials
Tarantino, P., & Curigliano, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1598372 · Cited by 16
“microbiome in ICI response, although more studies are needed to define its role in clinical practice [11].”
BackgroundGevaert, T., Cimadamore, A., Eckstein, M., Scarpelli, M., López-Beltrán, A., Cheng, L., & Montironi, R. (2019) · Future Oncology · doi:10.2217/fon-2019-0217 · Cited by 16
Hickey, J. W., Becker, W. R., Nevins, S. A., Horning, A. M., Espín-Pérez, A., Chiu, R., Chen, D. C., Cotter, D. J., Esplin, E. D., Weimer, A. K. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.25.469203 · Cited by 16
“…localization and cellular interactions in the gut is critical for understanding oral vaccine design 15 , interactions regulating the gut microbiota 16 , regulation of allergic food responses 17 , axes critical for wound repair 18 , and immune system responses and immunotherapies for cancer 19–22 .”
BackgroundMicrobiome-metabolome interplay in pancreatic cancer progression: insights from multi-omics analysis
Luo, D., Chen, Q., Li, Y., Yang, J., Tao, Y., Ji, L., & Gong, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02458-9 · Cited by 19
“Therefore, targeting the microbiota in pancreatic tumors increases the effectiveness of immune therapy and chemotherapy [15, 61].”
Comprehensive analysis of microbiota signature across 32 cancer types
Yang, X., An, H., He, Y., Fu, G., & Jiang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1127225 · Cited by 22
Preißner, S., Heiland, M., Preißner, R., Wirth, M., & Wollenberg, B. (2023) · Cancers · doi:10.3390/cancers15082342 · Cited by 15
“Very early on in the checkpoint treatment, several groups published data which found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, thereby [16,17] unravelling the importance of the commensal microbiota in immunooncology.”
BackgroundQi, Y., Zhuang, Z., Zeng, S., Tang, Y., Cheng, H. L., Cheng, S., & Zhang, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312201 · Cited by 15
Nara, K., Taguchi, S., Buti, S., Kawai, T., Uemura, Y., Yamamoto, T., Kume, H., & Takada, T. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008806 · Cited by 16
Wang, X., Xu, T., Wu, S., Li, L., Cai, X., Chen, F., & Yan, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216814 · Cited by 16
Metadata
- Authors
- Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F.
- Affiliations
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Centre National de la Recherche Scientifique (FR)
- Sorbonne Paris Cité (FR)
- University of Chicago (US)
- Corresponding author
- Zitvogel, Laurence
- Gajewski, Thomas F.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1366-1370
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791926234
- Cited by
- 777
- References
- 74
- Citations by year
- 2026: 84 · 2025: 85 · 2024: 74 · 2023: 96 · 2022: 84 · 2021: 130 · 2020: 105 · 2019: 81 · 2018: 37
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Melanoma Research Alliance (CA210098)
- University of Chicago (T32 CA009594)
- Association pour la Recherche sur le Cancer
- Seerave Foundation
- Jounce Therapeutics
- Incyte
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-10-LABX-0015)
- Fondation Leducq
- National Natural Science Foundation of China (81671630, CAMS-I2M, 2017YFA0506200, 81722037)
- Fondation pour la Recherche Médicale
- Government of Jiangsu Province
- Ligue Contre le Cancer
- Natural Science Foundation of Jiangsu Province (BK20170006, BK20160379)
- Institut Universitaire de France
- Chinese Academy of Medical Sciences (2016‐I2M‐1‐005, (CAMS-I2M), 2017RC31008, 2017NL31004, 2016ZX310194)
- Institut National Du Cancer
- Institut Gustave-Roussy
- Recruitment Program of Global Experts
- Genentech
- University of Chicago Medicine
- National Key Research and Development Program of China (2017YFA0506200)
- Labex Immuno-Oncology
- Comprehensive Cancer Center, University of Chicago Medical Center (T32 CA009594)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, host-microbe interactions, precision medicine, microbiome-based diagnostics, microbiota-based therapy, cancer immunotherapy resistance
- MeSH terms
- Gastrointestinal Microbiome, Humans, Immune System, Immunotherapy, Neoplasms, Treatment Outcome, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.